<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01537536</url>
  </required_header>
  <id_info>
    <org_study_id>IJBNeoEndoTAG-1</org_study_id>
    <nct_id>NCT01537536</nct_id>
  </id_info>
  <brief_title>Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer</brief_title>
  <acronym>EndoTAG-1</acronym>
  <official_title>An Open-label Phase II Trial Evaluating the Efficacy and Safety of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in Patients With HER2-negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jules Bordet Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jules Bordet Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is that the new drug EndoTAG-1 will improve tumor volume reduction as&#xD;
      measured by Magnetic Resonance Imaging when added to a standard chemotherapy regimen of&#xD;
      weekly paclitaxel. This is a prospective single-center study that will investigate the&#xD;
      activity of EndoTAG-1 + paclitaxel combination therapy in patients with HER2-negative breast&#xD;
      cancer that are candidate for receiving chemotherapy before surgery (neoadjuvant&#xD;
      chemotherapy).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-center, open-label phase II clinical trial investigating the&#xD;
      activity of EndoTAG-1 + paclitaxel combination therapy in patients with HER2-negative BC&#xD;
      candidate for neoadjuvant chemotherapy, as measured by the decrease in MRI-estimated tumour&#xD;
      volume at the end of EndoTAG-1 + paclitaxel administration. Patients will be stratified by&#xD;
      hormone receptor status.&#xD;
&#xD;
      A total of 20 female patients with non-metastatic HER2-negative breast cancer candidate for&#xD;
      neoadjuvant chemotherapy and meeting all study eligibility criteria will receive 12 weekly&#xD;
      infusions of EndoTAG-1 (22 mg/m2 liposomal paclitaxel) in combination with paclitaxel (70&#xD;
      mg/m2) followed by 3 cycles of FEC (Fluorouracil 500mg/m2, Epirubicin 100mg/m2,&#xD;
      Cyclophosphamide 500mg/m2) every 3 weeks (experimental group) The study hypothesis is that&#xD;
      EndoTAG-1 will improve MRI- estimated volume reduction when added to weekly paclitaxel. The&#xD;
      null hypothesis is that combination has no or a negligible effect on volume reduction&#xD;
      (defined as lower or equal to a 50% decrease) versus the alternative hypothesis that the&#xD;
      combination yields at least a 80% average decrease in MRI- estimated volume at the end of&#xD;
      weekly paclitaxel and EndoTAG-1 administration from baseline&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRI-estimated tumour volume at the end of neoadjuvant EndoTAG-1 + paclitaxel administration vs. baseline.</measure>
    <time_frame>15 weeks after start of neoadjuvant chemotherapy.</time_frame>
    <description>To investigate the activity of EndoTAG-1 + paclitaxel combination therapy in patients with HER2-negative BC candidate for neoadjuvant chemotherapy, as measured by the decrease in MRI-estimated tumour volume at the end of neoadjuvant EndoTAG-1 + paclitaxel administration vs. baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of pathological complete response (pCR).</measure>
    <time_frame>27 weeks after start of neoadjuvant chemotherapy.</time_frame>
    <description>Rate of pathological complete response (pCR) at the end of neo-adjuvant chemotherapy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>EndoTAG-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly treatment with EndoTAG-1 (22 mg/m2) plus paclitaxel (70 mg/m2) for 12 weeks (ET+P) followed by subsequent treatment with the standard FEC regimen (Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2) once every 3 weeks for 3 cycles of therapy followed by surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EndoTAG-1</intervention_name>
    <description>EndoTAG-1 (22 mg/m2 liposomal paclitaxel) + Paclitaxel (70 mg/m2) Weekly i.v. infusions of EndoTAG-1 and paclitaxel for 12 weeks followed by subsequent treatment with the standard FEC regimen (Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2) once every 3 weeks for 3 cycles of therapy followed by surgery.</description>
    <arm_group_label>EndoTAG-1</arm_group_label>
    <other_name>Non applicable</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. newly diagnosed histologically confirmed BC with breast infiltrating carcinoma of&#xD;
             histological grade &gt; 1 (either operable, or locally advanced or inflammatory)&#xD;
             candidate for neoadjuvant chemotherapy&#xD;
&#xD;
          2. HER2-negative tumor, defined according to immunohistochemistry or using fluorescent&#xD;
             in-situ hybridization (FISH)&#xD;
&#xD;
          3. ECOG performance status 0 or 1&#xD;
&#xD;
          4. Gender: female&#xD;
&#xD;
          5. Age : &gt;= 18 years old&#xD;
&#xD;
          6. Negative pregnancy test (females of childbearing potential)&#xD;
&#xD;
          7. Willingness to perform double-barrier-contraception during study and for 6 months post&#xD;
             chemotherapy treatment (females of childbearing potential)&#xD;
&#xD;
          8. Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Metastatic or relapsed disease&#xD;
&#xD;
          2. Major surgery &lt; 3 weeks prior to enrollment&#xD;
&#xD;
          3. Severe pulmonary obstructive or restrictive disease&#xD;
&#xD;
          4. Uncontrolled inflammatory disease (autoimmune or infectious)&#xD;
&#xD;
          5. Clinically significant cardiac disease (NYHA stadium &gt; 2)&#xD;
&#xD;
          6. Results of laboratory tests (hematology, chemistry) outside specified limits:&#xD;
&#xD;
               -  WBC ≤ 3 x 109/L&#xD;
&#xD;
               -  ANC &lt; 1.5 x 109/L&#xD;
&#xD;
               -  Platelets &lt; 100 x 109/L&#xD;
&#xD;
               -  Hb ≤ 9.0 g/dl (≤ 5.6 mmol/l)&#xD;
&#xD;
               -  PTT/ INR &gt; 1.5 x ULN&#xD;
&#xD;
               -  AST or ALT &gt; 2.5 x ULN&#xD;
&#xD;
               -  Alkaline Phosphatase &gt; 2 x ULN&#xD;
&#xD;
               -  Total Bilirubin &gt; 1.5 x ULN&#xD;
&#xD;
          7. Pregnancy or nursing status&#xD;
&#xD;
          8. Known positive HIV testing&#xD;
&#xD;
          9. Known hypersensitivity to any component of the EndoTAG-1, paclitaxel or FEC&#xD;
             formulations&#xD;
&#xD;
         10. History of malignancy other than breast cancer &lt; 5 years prior to enrollment, except&#xD;
             skin cancer (i.e. basal or squamous cell carcinoma) treated locally&#xD;
&#xD;
         11. History of active or significant neurological disorder or psychiatric disorder that&#xD;
             would prohibit the understanding and giving of informed consent, or would interfere in&#xD;
             the clinical and radiological evaluation of central nervous system during the trial&#xD;
&#xD;
         12. Concurrent treatment with other experimental products. Participation in another&#xD;
             clinical trial with any investigational product within 30 days prior to study entry&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michail Ignatiadis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jules Bordet Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>September 20, 2011</study_first_submitted>
  <study_first_submitted_qc>February 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2012</study_first_posted>
  <last_update_submitted>June 14, 2013</last_update_submitted>
  <last_update_submitted_qc>June 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <keyword>EndoTAG-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

